RE:RE:RE:RE:RE:RE:RE:RE:RE:Anyone think it was oddI like the explanation, but in my head I would analogize it to mass mail marketing to digital marketing. With mass mail, you are sending leaflets out to everyone hoping that the right people look at them, while with digital marketing you are targeting the add to those that most likely be influenced by it. Sortelin is like your browsing history, while the peptide is the code that targets the ads to that specific type of browsing.
realitycheck4u wrote: I felt it needed an analogy.
Here is my idea.
TH targets two massive markets and has one drug moving into PH3 after 10 years of safety proven in HIV patients.
TH’s oncology program just received FDA Fast Track status from earlier results and TH will be dosing patients shortly in a phase 1 study, after what can only be described as spectacular results in the lab with mice. This potentially revolutionary program is based around the idea of a Peptide, which is like a suitcase with sticky material on the outside, which will only stick to the membrane of a cancer sell which are expressing Sortilin - and this is significant as it is now known that Sortilin is within 5 different types of solid growth tumours. They are 1.2.3.4.5. (List them) What happens is that TH’s Peptide hunts for cells expressing Sortilin, then as soon as it’s near these cancers cells, the sticky material actually binds itself to the cancer membrane. Once the PDC is bound to the sortilin receptor, both are internalized into the cancer cell through a process called endocytosis. Once inside the cancer cell, the higher acidity, in comparison with the bloodstream, allows the release of the free anticancer agent. The sortilin receptor is the target to allow selective intake of the drug into the cancer cell. The other key part is the 17 amino acids peptide that has high affinity to the sortilin receptor that will lead to the specific binding of the two parts. The other critical feature of the peptide is the possibility to link to it two drug molecules through the use of a linker stable in the bloodstream, but unstable inside the cancer cells due to higher acidity. So this platform through the use of a proprietary peptide allows the selective intracellular delivery of cancer drugs. The advantages of this technique is that it allows higher concentration of the drug delivered directly to a cancer cell, and do that delivery INSIDE the cancer cells. It’s like Uber, but it does not drop you off 5 blocks away, but it targets the delivery right into your living room. And it can therefore deliver few cancer killing drugs with the same affect (as it’s delivered to your living room) or, it can deliver more of a dose to the actual cancer - while at the same time there is a much lower concentration impacting other healthy cells, leading to higher anti-cancer efficacy and lower toxicity in animal models with human cancer xenograft overexpressing the sortilin receptor.
MHemorrhage wrote: Thank you, editing this in!
jfm1330 wrote:
My version of this part.
Their cancer drugs TH1902 and TH1904 are peptide-drug conjugates (PDCs). The proprietary peptide (TH19P01) is a ligand to sortilin, a receptor expressed in many types of cancer and also a drug carrier since different drugs can be linked covalently to the it by a selectively cleavable linker. In the case of TH1902 the drug linked to the peptide is doxorubicin, and in the case of TH1904, it is docetaxel, both are generic, highly toxic, well known anti-cancer drugs. The innovative approach for the cancer program is that the PDCs allows to deliver free cytotoxic agents inside the cancer cells while protecting healthy cells. So the peptide part of the PDC allows the linking of the cytotoxic drugs on it while retaining the abilty of specific binding to the sortilin receptor expressed on the outside membrane of cancer cells. Once the PDC is bound to the sortilin receptor, both are internalized into the cancer cell through a process called endocytosis. Once inside the cancer cell, the higher acidity, in comparison with the bloodstream, allows the cleavage of the linker and the release of the free anticancer agent. The key to this oncology platform is the overexpression of the sortilin receptor in many types of cancer. The sortilin receptor is the target to allow selective intake of the drug into the cancer cell. The other key part is the 17 amino acids peptide that has high affinity to the sortilin receptor that will lead to the specific binding of the two parts. The other critical feature of the peptide is the possibility to link to it two drug molecules through the use of a linker stable in the bloodstream, but unstable inside the cancer cells due to higher acidity. So this platform through the use of a proprietary peptide allows the selective intracellular delivery of cancer drugs. The advantages of this technique is that it allows higher concentration of the drug in the cancer cells, and much lower concentration in other healthy cells, leading to higher anti-cancer efficacy and lower toxicity in animal models with human cancer xenograft overexpressing the sortilin receptor.